Brain-derived neurotrophic factor: Findings in schizophrenia

Current Opinion in Psychiatry

Volumn 24, Issue 2, 2011, Pages 122-127

  Buckley, Peter F ^a   Pillai, Anilkumar ^a   Howell, Kristy R ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

antipsychotic; brain derived neurotrophic factor; neuroplasticity; peripheral; psychosis; schizophrenia; Val66Met

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; NEUROTRANSMITTER;

ARTICLE; DEPRESSION; HUMAN; NERVE CELL PLASTICITY; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PSYCHOSIS; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

BRAIN-DERIVED NEUROTROPHIC FACTOR; HUMANS; POLYMORPHISM, GENETIC; SCHIZOPHRENIA;

EID: 79951581460     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/YCO.0b013e3283436eb7     Document Type: Article

References (93)

1. Tanaka S, Sekino Y, Shirao T. The effects of neurotrophin-3 and brain-derived neurotrophic factor on cerebellar granule cell movement and neurite extension in vitro. Neuroscience 2000; 97:727-734. (Pubitemid 30332179)
2. Thoenen H, Barde YA, Davies AM, Johnson JE. Neurotrophic factors and neuronal death. Ciba Found Symp 1987; 126:82-95.
3. Waterhouse EG, Xu B. New insights into the role of brain-derived neurotrophic factor in synaptic plasticity. Mol Cell Neurosci 2009; 42:81-89.
4. Lu Y, Christian K, Lu B. BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory? Neurobiol Learn Mem 2008; 89:312-323. (Pubitemid 351318269)
5. Arnold SE, Talbot K, Hahn CG. Neurodevelopment, neuroplasticity, and new genes for schizophrenia. Prog Brain Res 2005; 147:319-345.
6. Pillai A. Brain-derived neurotropic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia. Neurosignals 2008; 16:183-193. (Pubitemid 351263224)
7. Kuipers SD, Bramham CR. Brain-derived neurotrophic factor mechanisms and function in adult synaptic plasticity: new insights and implications for therapy. Curr Opin Drug Discov Devel 2006; 9:580-586. (Pubitemid 44378826)
8. Lessmann V, Gottmann K,MalcangioM. Neurotrophin secretion: current facts and future prospects. Prog Neurobiol 2003; 69:341-374. (Pubitemid 36645053)
9. Murer MG, Yan Q, Raisman-Vozari R. Brain derived neurotrophic factor in the control human brain, and in Alzheimer s disease and Parkinson s disease. Prog Neurobiol 2001; 63:71-124.
10. Bramham CR, Messaoudi E. BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Prog Neurobiol 2005; 76:99-125. (Pubitemid 41242884)
11. Arevalo JC, Wu SH. Neurotrophin signaling: many exciting surprises! Cell Mol Life Sci 2006; 63:1523-1537. (Pubitemid 44156749)
12. Biffo S, Offenhauser N, Carter BD, Barde YA. Selective binding and internalisation by truncated receptors restrict the availability of BDNF during development. Development 1995; 121:2461-2470.
13. Eide FF, Vining ER, Eide BL, et al. Naturally occurring truncated TrkB receptors have dominant inhibitory effects on brain-derived neurotrophic factor signaling. J Neurosci 1996; 16:3123-3129. (Pubitemid 26142348)
14. Ninkina N, Adu J, Fischer A, et al. Expression and function of TrkB variants in developing sensory neurons. EMBO J 1996; 15:6385-6393. (Pubitemid 26413771)
15. Numakawa T, Suzuki S, Kumamaru E, et al. BDNF function and intracellular signaling in neurons. Histol Histopathol 2010; 25:237-258.
16. Minichiello L, Korte M, Wolfer D, et al. Essential role for TrkB receptors in hippocampus-mediated learning. Neuron 1999; 24:401-414. (Pubitemid 29508413)
17. Xu B, Gottschalk W, Chow A, et al. The role of brain-derived neurotrophic factor receptors in the mature hippocampus: modulation of long-term potentiation through a presynaptic mechanism involving TrkB. J Neurosci 2000; 20:6888-6897.
18. Gärtner A, Polnau DG, Staiger V, et al. Hippocampal long-term potentiation is supported by presynaptic and postsynaptic tyrosine receptor kinase B-mediated phospholipase Cgamma signaling. J Neurosci 2006; 26:3496 3504.
19. Linnarsson S, Björklund A, Ernfors P. Learning deficit in BDNF mutant mice. Eur J Neurosci 1997; 9:2581-2587. (Pubitemid 28082947)
20. Tyler WJ, Alonso M, Bramham CR, Pozzo-Miller LD. From acquisition to consolidation: on the role of brain-derived neurotrophic factor signaling in hippocampal-dependent learning. Learn Mem 2002; 9:224-237.
21. Cirulli F, Berry A, Chiarotti F, Alleva E. Intrahippocampal administration of BDNF in adult rats affects short-term behavioral plasticity in the Morris water maze and performance in the elevated plus-maze. Hippocampus 2004; 14:802-807. (Pubitemid 39517457)
22. Figurov A, Pozzo-Miller LD, Olafsson P, et al. Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature 1996; 381:706-709. (Pubitemid 26196571)
23. Kang H, Welcher AA, Shelton D, Schuman EM. Neurotrophins and time: different roles for TrkB signaling in hippocampal long-term potentiation. Neuron 1997; 19:653-664. (Pubitemid 27430751)
24. Shimada A, Mason CA, Morrison ME. TrkB signaling modulates spine density and morphology independent of dendrite structure in cultured neonatal Purkinje cells. J Neurosci 1998; 18:8559-8570. (Pubitemid 28491723)
25. Yacoubian TA, Lo DC. Truncated and full-length TrkB receptors regulate distinct modes of dendritic growth. Nat Neurosci 2000; 3:342-349. (Pubitemid 30185484)
26. Lu B, Chang J. Regulation of neurogenesis by neurotrophins: implications in hippocampus-dependent memory. Neuron Glia Biol 2005; 1:377-384.
27. Sairanen M, Lucas G, Ernfors P, et al. Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J Neurosci 2005; 25:1089-1094. (Pubitemid 40268949)
28. McBain CJ, Fisahn A. Interneurons unbound. Nat Rev Neurosci 2001; 2:11-23. (Pubitemid 33673345)
29. Akbarian S, Kim JJ, Potkin SG, et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 1995; 52:258-266.
30. Guidotti A, Auta J, Davis JM, et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 2000; 57:1061-1069.
31. Volk DW, Austin MC, Pierri JN, et al. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gammaaminobutyric acid neurons in subjects with schizophrenia. Arch Gen Psychiatry 2000; 57:237-245. (Pubitemid 30140433)
32. Hashimoto T, Bergen SE, Nguyen QL, et al. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci 2005; 25:372-383. (Pubitemid 40105607)
33. Mizuno K, Carnahan J, Nawa H. Brain-derived neurotrophic factor promotes differentiation of striatal GABAergic neurons. Dev Biol 1994; 165:243-256. (Pubitemid 24306118)
34. Arenas E, Akerud P, Wong V, et al. Effects of BDNF and NT-4/5 on striatonigral neuropeptides or nigral GABA neurons in vivo. Eur J Neurosci 1996; 8:1707-1717.
35. Brünig I, Penschuck S, Berninger B, et al. BDNF reduces miniature inhibitory postsynaptic currents by rapid downregulation of GABA(A) receptor surface expression. Eur J Neurosci 2001; 13:1320 1328.
36. Elmariah SB, Crumling MA, Parsons TD, Balice-Gordon RJ. Postsynaptic TrkB-mediated signaling modulates excitatory and inhibitory neurotransmitter receptor clustering at hippocampal synapses. J Neurosci 2004; 24:2380-2393. (Pubitemid 38327951)
37. Henneberger C, Kirischuk S, Grantyn R. Brain-derived neurotrophic factor modulates GABAergic synaptic transmission by enhancing presynaptic glutamic acid decarboxylase 65 levels, promoting asynchronous release and reducing the number of activated postsynaptic receptors. Neuroscience 2005; 135:749-763. (Pubitemid 41407739)
38. Yamada MK, Nakanishi K, Ohba S, et al. Brain-derived neurotrophic factor promotes the maturation of GABAergic mechanisms in cultured hippocampal neurons. J Neurosci 2002; 22:7580-7585. (Pubitemid 35386359)
39. Vicario-Abejón C, Collin C, McKay RD, Segal M. Neurotrophins induce formation of functional excitatory and inhibitory synapses between cultured hippocampal neurons. J Neurosci 1998; 18:7256 7271. (Pubitemid 28425811)
40. Huang ZJ, Kirkwood A, Pizzorusso T, et al. BDNF regulates the maturation of inhibition and the critical period of plasticity in mouse visual cortex. Cell 1999; 98:739-755. (Pubitemid 29446892)
41. Bao S, Chen L, Qiao X, Thompson RF. Transgenic brain-derived neurotrophic factor modulates a developing cerebellar inhibitory synapse. Learn Mem 1999; 6:276-283. (Pubitemid 29422830)
42. Spina MB, Squinto SP, Miller J, et al. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4- phenylpyridinium ion toxicity: involvement of the glutathione system. J Neurochem 1992; 59:99-106.
43. Williams SN, Undieh AS. Dopamine D1-like receptor activation induces brainderived neurotrophic factor protein expression. Neuroreport 2009; 20:606-610.
44. Hasbi A, Fan T, Alijaniaram M, et al. Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth. Proc Natl Acad Sci U S A 2009; 106:21377-21382.
45. Eaton MJ, Whittemore SR. Autocrine BDNF secretion enhances the survival and serotonergic differentiation of raphe neuronal precursor cells grafted into the adult rat CNS. Exp Neurol 1996; 140:105-114. (Pubitemid 26254892)
46. Rumajogee P, Vergé D, Hanoun N, et al. Adaption of the serotoninergic neuronal phenotype in the absence of 5-HT autoreceptors or the 5-HT transporter: involvement of BDNF and cAMP. Eur J Neurosci 2004; 19:937-944. (Pubitemid 38297031)
47. Djalali S, Höltje M, Grosse G, et al. Effects of brain-derived neurotrophic factor (BDNF) on glial cells and serotonergic neurones during development. J Neurochem 2005; 92:616-627. (Pubitemid 40189464)
48. Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112:257-269. (Pubitemid 36144114)
49. Pang PT, Teng HK, Zaitsev E, et al. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 2004; 306:487-491. (Pubitemid 39372449)
50. Chung S, Chung HY, Jung J, et al. Association among aggressiveness, neurocognitive function, and the Val66Met polymorphism of brain-derived neurotrophic factor gene in male schizophrenic patients. Compr Psychiatry 2010; 51:367-372.
51. Spalletta G, Morris DW, Angelucci F, et al. BDNF Val66Met polymorphism is associated with aggressive behavior in schizophrenia. Eur Psychiatry 2010; 25:311-313.
52. Dempster E, Toulopoulou T, McDonald C, et al. Association between BDNF Val(66)Met genotype and episodic memory. Am J Med Genet B Neuropsychiatr Genet 2005; 134B:73-75. (Pubitemid 40411113)
53. Ho BC, Milev P,O Leary DS, et al. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch Gen Psychiatry 2006; 63:731-740.
54. Goldberg TE, Iudicello J, Russo C, et al. BDNF Val66Met polymorphism significantly affects d0 in verbal recognition memory at short and long delays. Biol Psychol 2008; 77:20-24. (Pubitemid 350309702)
55. Strauss J, Barr CL, George CJ, et al. BDNF and COMT polymorphisms: relation to memory phenotypes in young adults with childhood-onset mood disorder. Neuromol Med 2004; 5:181-192. (Pubitemid 40125300)
56. Oroszi G, Lapteva L, Davis E, et al. The Met66 allele of the functional Val66Met polymorphismin the brain-derived neurotrophic factor gene confers protection against neurocognitive dysfunction in systemic lupus erythematosus. Ann Rheum Dis 2006; 65:1330-1335. (Pubitemid 44620442)
57. Pezawas L, Verchinski BA, Mattay VS, et al. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci 2004; 24:10099-10102. (Pubitemid 39492034)
58. Wassink CS, Nelson JJ, Crowe RR, Andreasen NC. Heritability of BDNF alleles and their effect on brain morphology in schizophrenia. Am J Med Genet 1999; 88:724-728.
59. Szeszko PR, Lipsky R, Mentschel C, et al. Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation. Mol Psychiatry 2005; 10:631-636. (Pubitemid 40961733)
60. Bath KG, Lee FS. Variant BDNF (Val66Met) impact on brain structure and function. Cogn Affect Behav Neurosci 2006; 6:79-85.
61. Hariri AR, Goldberg TE, Mattay VS, et al. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 2003; 23:6690-6694. (Pubitemid 36951196)
62. Chen ZY, Jing D, Bath KG, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 2006; 314:140-143. (Pubitemid 44547760)
63. Weickert CS, Hyde TM, Lipska BK, et al. Reduced brain derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2003; 8:592-610. (Pubitemid 36898018)
64. Durany N, Michel T, Zochling R, et al. Brain derived neurotrophic factor and neurotrophin-3 in schizophrenic psychoses. Schizophr Res 2001; 52:79-86. (Pubitemid 32947050)
65. Issa G, Wilson C, Terry AV Jr, Pillai A. An inverse relationship between cortisol and BDNF levels in schizophrenia: data from human postmortem and animal studies. Neurobiol Dis 2010; 39:327-333.
66. Buckley PF, Pillai A, Evans D, et al. Brain derived neurotropic factor in firstepisode psychosis. Schizophr Res 2007; 91:1-5.
67. Chen da C, Wang J, Wang B, et al. Decreased levels of serum brain-derived neurotrophic factor in drug-naive first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology (Berl) 2009; 207:375-380.
68. Jindal RD, Pillai AK, Mahadik SP, et al. Decreased BDNF in patients with antipsychotic naive first episode schizophrenia. Schizophr Res 2010; 119:47-51.
69. Pillai A, Kale A, Joshi S, et al. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. Int J Neuropsychopharmacol 2010; 13:535-539.
70. Xiu MH, Hui L, Dang YF, et al. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:1508-1512.
71. Reis HJ, Nicolato R, Barbosa IG, et al. Increased serum levels of brain-derived neurotrophic factor in chronic institutionalized patients with schizophrenia. Neurosci Lett 2008; 439:157-159.
72. Rizos EN, Papadopoulou A, Laskos E, et al. Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J Biol Psychiatry 2010; 11 (2 Pt 2): 251-255.
73. Vinogradov S, Fisher M, Holland C, et al. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia? Biol Psychiatry 2009; 66:549-553.
74. Toyooka K, Asama K, Watanabe Y, et al. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 2002; 110:249-257. (Pubitemid 34804533)
75. Grillo RW, Ottoni GL, Leke R, et al. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res 2007; 41:31-35. (Pubitemid 44708213)
76. Ikeda Y, Yahata N, Ito I, et al. Low serum levels of brain-derived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia. Schizophr Res 2008; 101:58-66.
77. Iritani S, Niizato K, Nawa H, et al. Immunohistochemical study of brain-derived neurotrophic factor and its receptor, TrkB, in the hippocampal formation of schizophrenic brains. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:801-807. (Pubitemid 36966762)
78. Gama CS, Andreazza AC, Kunz M, et al. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci Lett 2007; 420:45-58.
79. Zhang XY, Tan YL, Zhou DF, et al. Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics. J Psychiatr Res 2007; 41:997-1004. (Pubitemid 47304448)
80. Palomino A, Vallejo-Illarramendi A, González-Pinto A, et al. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr Res 2006; 86:321-322. (Pubitemid 44234056)
81. Hashimoto T, Bergen SE, Nguyen QL, et al. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci 2005; 25:372-383. (Pubitemid 40105607)
82. Takahashi M, Shirakawa O, Toyooka K, et al. Abnormal expression of brainderived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 2000; 5:292-300.
83. Hori H, Yoshimura R, Yamada Y, et al. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int Clin Psychopharmacol 2007; 22:21-27. (Pubitemid 44950764)
84. Yoshimura R, Hori H, Sugita A, et al. Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1072-1077. (Pubitemid 46810098)
85. Carlino D, Leone E, Di Cola F, et al. Low serum truncated-BDNF isoform correlates with higher cognitive impairment in schizophrenia. J Psychiatr Res 2011; 45:273-279.
86. Sato M, Numachi Y, Hamamura T. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr Bull 1992; 18:115-122.
87. Walker E, Mittal V, Tessner K. Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annu Rev Clin Psychol 2008; 4:189-216. (Pubitemid 351668616)
88. Whitehead C, Moss S, Cardno A, Lewis G. Antidepressants for the treatment of depression in people with schizophrenia: a systematic review. Psychol Med 2003; 33:589-599. (Pubitemid 36626041)
89. Rummel C, Kissling W, Leucht S. Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials. Schizophr Res 2005; 80:85-97. (Pubitemid 41587466)
90. Siris SG, Bermanzohn PC, Mason SE, Shuwall MA. Maintenance imipramine therapy for secondary depression in schizophrenia: a controlled trial. Arch Gen Psychiatry 1994; 51:109-115. (Pubitemid 24054312)
91. Mulholland C, Lynch G, King DJ, Cooper SJ. A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia. J Psychopharmacol 2003; 17:107-112. (Pubitemid 36373148)
92. Zisook S, Kasckow JW, Golshan S, et al. Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial. J Clin Psychiatry 2009; 70:562-571.
93. Castrén E, Rantamä ki T. The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev Neurobiol 2010; 70:289-297.